美国生物医药产业竞争力分析与启示

doi:10.13523/j.cb.2005017

中国生物工程杂志

2020, Vol. 40

Issue (9): 87-94 DOI: 10.13523/j.cb.2005017

行业分析

美国生物医药产业竞争力分析与启示

尹政清^1,^*(

),白京羽²,林晓锋²

1中国农业大学信息与电气工程学院北京 100083
2国家发展和改革委员会创新驱动发展中心北京 100037

Competitiveness Analysis and Enlightenment of Biomedical Industry in USA

YIN Zheng-qing^1,^*(

),BAI Jing-yu²,LIN Xiao-feng²

1 College of Information and Electrical Engineering, China Agricultural University, Beijing 100083,China
2 Innovation Driven Development Center, National Development and Reform Commission, Beijing 100037,China

全文: PDF(2458 KB) HTML

摘要：

进入生物经济时代以来,以生物医药产业为代表的生物技术产业正在引领人类新一波技术产业革命。我国针对生物医药产业作出的战略部署已经取得了明显成效,但与美国等生物医药强国相比仍有较大的竞争差距。采用波特钻石模型构建了生物医药产业国际竞争力理论分析框架,以美国为例分析其生物医药产业在要素状况、企业结构和竞争、需求条件、相关及支持性产业、政府和发展机会六个方面的竞争优势,并基于此提出了我国发展生物医药产业的政策建议,从而为我国生物医药产业发展提供政策参考。

关键词： 生物医药产业; 美国; 国际竞争力; 波特钻石模型; 政策建议

Abstract:

Represented by the biomedical industry, the bio-industry is leading a new wave of technological industry revolution since mankind entered the era of bioeconomy. China’s strategic deployment for the biopharmaceutical industry has achieved significant results. However, it still has a large competitive gap compared with the powerhouses of biomedical industry such as the United States. The Porter’s diamond model is employed to construct a conceptual framework for the international competitiveness of the biomedical industry, taking the United States as an example to analyze its biomedical industry from six perspectives:(1)Factor conditions;(2) Enterprise structure and competition;(3) Demand conditions;(4)Related and supporting industries;(5)The role of government;(6) Development opportunities. Finally, related policy recommendations for China’s biomedical industry development are put forward,so as to provide policy reference for the development of China’s biomedical industry.

Key words: Biomedical industry The United States of America International competitiveness The Porter’s Diamond Model Policy recommendations

收稿日期: 2020-05-11 出版日期: 2020-10-12

ZTFLH:

R-1

通讯作者: 尹政清 E-mail: yzq_cau@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	尹政清
	白京羽
	林晓锋

引用本文:

尹政清,白京羽,林晓锋. 美国生物医药产业竞争力分析与启示[J]. 中国生物工程杂志, 2020, 40(9): 87-94.

YIN Zheng-qing,BAI Jing-yu,LIN Xiao-feng. Competitiveness Analysis and Enlightenment of Biomedical Industry in USA. China Biotechnology, 2020, 40(9): 87-94.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2005017 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I9/87

图1 基于波特钻石模型的生物医药产业竞争力分析框架

表1 2019年全球生物医药公司研发强度、创新力和市值排名

图2 2010~2017年美国生物医药行业就业情况

图3 2010~2019年美国生物医药产业并购金额

图4 1995~2019年美国FDA批准上市的新药数量

[1]	石光, 刘芳瑜. 我国生物医药产业发展的现状与对策. 中国卫生政策研究, 2016,9(3):16-19.
	Shi G, Liu F Y. The status quo and strategies on biotechnological medicine industry development in China. Chinese Journal of Health Policy, 2016,9(3):16-19.
[2]	Morrison C. 2019 biotech IPOs: Party on. Nature Reviews Drug Discovery, 2020,49(1):6-9.
[3]	郭中平. 生物药和生物类似药研究的现状与发展. 临床药物治疗杂志, 2020,18(5):1-6.
	Guo Z P. Current situation and development in research on biotherapeutic and biosimilars. Clinical Medication Journal, 2020,18(5):1-6.
[4]	Hodgson J. Biotech’s baby boom. Nature Biotechnology, 2019,37(5):502-512. doi: 10.1038/s41587-019-0112-4 pmid: 31053818
[5]	中华人民共和国科学技术部. 美国发布《国家生物经济蓝图》. [2020-06-14]. http://www.most.gov.cn/gnwkjdt/201206/t20120612_94963.htm.
	Ministry of Science and Technology of the People’s Republic of China. . U.S. releases “National Bioeconomic Blueprint”. [2020-06-14]. http://www.most.gov.cn/gnwkjdt/201206/t20120612_94963.htm.
[6]	中华人民共和国国务院. “十三五”国家科技创新规划. [2020-06-14]. http://www.gov.cn/zhengce/content/2016-08/08/content_5098072.htm.
	State Council of the People’s Republic of China. National science and technology innovation plan of “the 13th Five-year Plan”. [2020-06-14]. http://www.gov.cn/zhengce/content/2016-08/08/content_5098072.htm.
[7]	国家发展改革委. “十三五”生物产业发展规划. [2020-06-14]. https://www.ndrc.gov.cn/fggz/fzzlgh/gjjzxgh/201706/W020191104624250601539.pdf.
	National Development and Reform Commission. Biological industry development plan of “the 13th Five-year Plan”. [2020-06-14]. https://www.ndrc.gov.cn/fggz/fzzlgh/gjjzxgh/201706/W020191104624250601539.pdf.
[8]	钱景怡, 余正. 我国生物制药产业国际竞争力分析. 中国药事, 2020,34(5):549-555.
	Qian J Y, Yu Z. On the international competitiveness of China’s bio-pharmaceutical industry. Chinese Pharmaceutical Affairs, 2020,34(5):549-555.
[9]	Carlson R. Estimating the biotech sector’s contribution to the US economy. Nature Biotechnology, 2016,34(3):247-255. pmid: 26963545
[10]	张金昌. 国际竞争力评价的理论和方法研究. 北京: 中国社会科学院研究生院, 2001.
	Zhang J C. Research on the theory and method of international competitiveness evaluation. Beijing: Graduate School of Chinese Academy of Social Sciences, 2001.
[11]	Irfan M, Zhao Z Y, Ahmad M, et al. Critical factors influencing wind power industry: A Diamond Model based study of India. Energy Reports, 2019,5(1):1222-1235.
[12]	Fang K, Zhou Y H, Wang S, et al. Assessing national renewable energy competitiveness of the G20: A revised Porter’s Diamond Model. Renewable and Sustainable Energy Reviews, 2018,93(1):719-731.
[13]	Chung T W. A study on logistics cluster competitiveness among Asia main countries using the Porter’s Diamond Model. The Asian Journal of Shipping and Logistics, 2016,32(4):257-264.
[14]	Özer K O, Latif H, Sariisik M, et al. International competitive advantage of Turkish tourism industry: A comperative analyse of Turkey and Spain by using the Diamond Model of M. Porter. Procedia - Social and Behavioral Sciences, 2012,58(1):1064-1076.
[15]	迈克尔·波特. 国家竞争优势. 北京: 华夏出版社, 2002: 123-136.
	Michael E P. Competitive advantage of nations. Beijing: Huaxia Publishing House, 2002: 123-136.
[16]	纪蕾, 李红艳, 王颖, 等. 基于钻石模型的山东省海洋生物医药产业竞争力分析. 渔业研究, 2019,41(5):430-440.
	Ji L, Li H Y, Wang Y, et al. Research on the competitiveness of marine bio pharmaceutical industry in Shandong Province based on diamond model. Journal of Fisheries Research, 2019,41(5):430-440.
[17]	赵冰, 张东生, 赵拥政. 区域生物医药产业基于钻石模型的竞争力研究:以石家庄为例. 中国生物工程杂志, 2011,31(9):140-145.
	Zhao B, Zhang D S, Zhao Y Z. Research on the competitiveness of regional biomedical industry:Taking Shijiazhuang as example. China Biotechnology, 2011,31(9):140-145.
[18]	Clarivate Analytics. Web of Science. [2020-06-14]. https://webofknowledge.com. pmid: 26293960
[19]	朱修篁, 易香华, 薛芳芳, 等. 生物医药专利分布及趋势研究. 中国新药杂志, 2015,24(15):1686-1693.
	Zhu X H, Yi X H, Xue F F, et al. Investigation and analysis of healthcare patents distribution and trend. Chinese Journal of New Drugs, 2015,24(15):1686-1693.
[20]	国家药品监督管理局. 全球药物研发数据库. [2020-06-10]. https://shuju.menet.com.cn.
	National Medical Products Administration. Global drug R&D database. [2020-06-10]. https://shuju.menet.com.cn.
[21]	Crunchbase. Crunchbase. [2020-03-31]. https://www.crunchbase.com.
[22]	Graul A I, Pina P, Cruces E, et al. 2018年全球新药研发报告第1部分:新药和生物制剂(Ⅰ). 药学进展, 2019,41(4):309-317.
	Graul A I, Pina P, Cruces E, et al. A report of new drugs research and development in 2018 Part I: New drugs & biologies (Ⅰ). Progress in Pharmaceutical Sciences, 2019,41(4):309-317.
[23]	Hernández H, Grassano N, Tübke A, et al. The 2019 EU industrial R&D investment scoreboard. Luxembourg: Publications Office of the European Union, 2019: 62.
[24]	Fast Company. The world’s 50 most innovative companies 2019. [2020-06-14]. https://www.fastcompany.com/most-innovative-companies/2019/sectors/biotech.
[25]	Fast Company. The world’s 50 most innovative companies 2018.[2020-06-14]. https://www.fastcompany.com/most-innovative-companies/2018/sectors/biotech.
[26]	Genetic Engineering and Biotechnology News. Top 25 biotech companies of 2019. [2020-06-14]. https://www.genengnews.com/a-lists/top-25-biotech-companies-of-2019.
[27]	Quacquarelli Symonds. The QS World University Rankings. [2020-06-14] https://www.topuniversities.com/university-rankings/university-subject-rankings/2020/biological-sciences.
[28]	Lindburg L, Bozinovic L, Susek R. As the life science industry evolves, so do its talent needs. Nature Biotechnology, 2019,37(4):481-483. pmid: 30940939
[29]	黄玮. 生物医药产业风险投资模式研究. 上海: 复旦大学, 2006.
	Huang W. Research on venture capital model of biomedical industry. Shanghai: Fudan University, 2006.
[30]	张佳睿. 美国生物医药产业发展的经验及启示. 商业研究, 2015,39(12):24-28.
	Zhang J R. Development experience of American biomedical industry and its enlightenment. Commercial Research, 2015,39(12):24-28.
[31]	火石创造. 2019年全球生物医药领域十大风险投资事件. [2020-06-14]. https://med.sina.com/article_detail_103_2_76424.html.
	Hsmap. Top 10 venture capital events in global biomedical field in 2019. [2020-06-14]. https://med.sina.com/article_detail_103_2_76424.html.
[32]	Ernst & Young. Beyond borders staying the course: Biotechnology report 2017. [2020-06-17]. http://www.ey.com/Publication/vwLUAssets/ey-biotechnology-report-2017-beyond-borders-staying-the-course/%24FILE/ey-biotechnology-report-2017-beyond-borders-staying-the-course.pdf.
[33]	郑晓奋. 美国生物技术产业集群创新及对我国的启示. 海南大学学报(人文社会科学版), 2011,29(3):50-54.
	Zheng X F. The cluster innovation of American biotechnology industry and its enlightenment to China. Humanities & Social Sciences Journal of Hainan University, 2011,29(3):50-54.
[34]	张擎. 美国生物医药产业园区发展特点及启示. 中国高新区, 2011,11(4):111-113.
	Zhang Q. Development characteristics and enlightenment of biomedical industrial park in the United States. Science & Technology Industry Parks, 2011,11(4):111-113.
[35]	JPMorgan. J. P. 2020 US Biotech Outlook. 38th Annual J.P. Morgan Healthcare Conference. San Francisco: JPMorgan, 2020: 73.
[36]	HBM Partners. HBM Pharma/Biotech M&A Report 2020 . [2020-06-14]. https://hbmpartners.com/media/docs/industry-reports/HBM-Pharma-Biotech-M-A-Report-2020.pdf.
[37]	Chen H M, Engkvist O, Wang Y H, et al. The rise of deep learning in drug discovery. Drug Discovery Today, 2018,23(6):1241-1250. doi: 10.1016/j.drudis.2018.01.039 pmid: 29366762
[38]	Zhang L, Tan J J, Han D, et al. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discovery Today, 2017,22(11):1680-1685. pmid: 28881183
[39]	王秀梅. 生物材料. 新型工业化, 2015,5(12):37-68.
	Wang X M. Biological material. The Journal of New Industrialization, 2015,5(12):37-68.
[40]	UN Comtrade. Commodity Trade Statistics Database. [2020-06-14]. https://comtrade.un.org.
[41]	World Bank. World Development Indicators.[ [2020-06-14]. http://databank.worldbank.org/data.
[42]	姚恒美. 美国生物医药产业发展态势. [2020-06-14]. http://www.istis.sh.cn/list/list.aspx?id=12372.
	Yao H M. . Development trend of biomedical industry in the United States. [2020-06-14]. http://www.istis.sh.cn/list/list.aspx?id=12372.
[43]	王飞. 美国生物医药产业创新的升级规律及启示. 南京社会科学, 2019,30(8):29-35.
	Wang F. Upgrading law and enlightenment of biomedical industry innovation in USA. Nanjing Journal of Social Sciences, 2019,30(8):29-35.
[44]	朱信凯, 涂圣伟, 杨顺江. 国际生物技术产业政策评论及对我国的启示. 中国软科学, 2005,20(11):18-23,76.
	Zhu X K, Tu S W, Yang S J. Comment on the international biotechnology industry policy and the revelation for our country.
[45]	中华人民共和国中央人民政府. 新型冠状病毒感染的肺炎诊疗方案(试行第三版). [2020-03-30]. http://www.gov.cn/zhengce/zhengceku/2020-01/23/5471832/files/106d59e45ac948ceb3cb12d400b8053c.pdf.
	The Central People’s Government of the People’s Republic of China. Diagnosis and treatment of COVID-19 (trial version third). [2020-03-30]. http://www.gov.cn/zhengce/zhengceku/2020-01/23/5471832/files/106d59e45ac948ceb3cb12d400b8053c.pdf.
[46]	Ledford H. The coronavirus outbreak could make it quicker and easier to trial drugs. Nature, 2020,582(1):172.
[47]	Hodgson J. The pandemic pipeline. Nature Biotechnology, 2020,38(5):523-532. pmid: 32203293

[1]	谭清立,林岱衡,刘珈瑗,林兴纯. 基于灰色综合关联分析法的粤港澳大湾区生物医药产业效益研究^*[J]. 中国生物工程杂志, 2021, 41(6): 89-97.
[2]	黄鹏飞,陈赟,陆娇,毛开云,袁银池. *生物医药专利密集型产业发展现状及建议^——以上海市为例**[J]. 中国生物工程杂志, 2020, 40(12): 108-116.
[3]	董心月,蒋蓉,里扎·阿德列提别克,邵蓉. 美国生物类似药的使用与医疗保险支付策略分析——基于Pfizer vs. Johnson案的思考 ^*[J]. 中国生物工程杂志, 2019, 39(12): 95-102.
[4]	卢姗, 李苏宁, 范红. 肿瘤免疫治疗技术与产品开发的现状与发展建议[J]. 中国生物工程杂志, 2017, 37(1): 104-110.
[5]	卢国栋, 张克山, 刘永杰, 尚佑军, 郭建宏, 郑海学, 田宏, 刘湘涛. 兽用疫苗管理与控制的国际标准[J]. 中国生物工程杂志, 2011, 31(5): 138-141.
[6]	卢国栋张克山刘永杰尚佑军郭建宏郑海学田宏刘湘涛. 兽用疫苗管理与控制的国际标准[J]. 中国生物工程杂志, 2011, 31(05): 0-0.
[7]	杜艳艳. 美国国家植物基因组计划资助情况分析[J]. 中国生物工程杂志, 2010, 30(04): 131-134.
[8]	刘润生. 美国先进生物燃料技术政策与态势分析[J]. 中国生物工程杂志, 2010, 30(01): 117-122.
[9]	苏月刘楠. 生物医药产业发展态势与对策[J]. 中国生物工程杂志, 2009, 29(11): 123-128.
[10]	李志军. 美国生物产业融资状况、特点与趋势分析[J]. 中国生物工程杂志, 2004, 24(9): 95-99.
[11]	郑海涛, 林珊莉, 吴翠玲. 产业集群导向的生物医药招商引资策略[J]. 中国生物工程杂志, 2004, 24(4): 86-88.
[12]	欧新黔. 求实创新,加快我国生物技术的发展[J]. 中国生物工程杂志, 2004, 24(2): 2-2.
[13]	马奎蒙. 美国修改专利法保护基因工程知识产权[J]. 中国生物工程杂志, 1993, 13(6): 53-55.
[14]	刘彦, 周永春. 向环境释放重组体生物的限制正逐步放宽[J]. 中国生物工程杂志, 1993, 13(3): 1-2.
[15]	戴秀玉. 美国妇女艾滋病问题讨论[J]. 中国生物工程杂志, 1993, 13(2): 49-52.

Viewed

Full text

Abstract

Cited

Shared

Discussed